Treatments for AD: towards the right target at the right time
- 1 September 2023
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 19 (10) , 581-582
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Trial of Solanezumab in Preclinical Alzheimer’s DiseaseNew England Journal of Medicine, 2023
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- Towards a future where Alzheimer’s disease pathology is stopped before the onset of dementiaNature Aging, 2023
- Large-scale cerebrospinal fluid proteomic analysis in Alzheimer’s disease patients reveals five molecular subtypes with distinct genetic risk profilesmedRxiv, 2023
- Lecanemab in Early Alzheimer’s DiseaseNew England Journal of Medicine, 2023
- Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression HeterogeneityNeurology, 2021
- Trial of Solanezumab for Mild Dementia Due to Alzheimer’s DiseaseNew England Journal of Medicine, 2018
- Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal PersonsJAMA, 2017